Aptose Biosciences price target raised to $50 from $9 at Oppenheimer

Oppenheimer raised the firm’s price target on Aptose Biosciences to $50 from $9 following the recent 15-1 reverse split, while keeping an Outperform rating on the shares. The firm notes Aptose provided a clinical update from tuspetinib dose expansion. Enrollment is progressing well, and a case study was shared from an unconfirmed CR in the venetoclax combination cohort, but detailed efficacy data otherwise weren’t provided. Oppenheimer’s most significant takeaway was that based on recent FDA feedback, a single-arm accelerated approval appears very much in play in certain tough-to-treat AML subpopulations.